Neuroblastoma arginine addiction subverts the anticancer immune response

Carmela De Santo; Francis Mussai

doi:10.1080/2162402X.2015.1078967

Neuroblastoma arginine addiction subverts the anticancer immune response

Carmela De Santo, Francis Mussai

Immunology and Immunotherapy

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

High-risk neuroblastoma continues to have a poor prognosis, stimulating the ongoing development of alternative immune-therapy approaches. Despite exciting preclinical results, clinical outcomes have been less clear. Recently we identified that neuroblastoma expresses Arginase II, depleting local and systemic arginine concentrations, and suppression of autologous and engineered T cell immunity.

Original language	English
Article number	e1078967
Number of pages	2
Journal	OncoImmunology
Volume	5
Issue number	2
DOIs	https://doi.org/10.1080/2162402X.2015.1078967
Publication status	Published - Feb 2016

Access to Document

10.1080/2162402X.2015.1078967Licence: None: All rights reserved

https://doi.org/10.1080/2162402X.2015.1078967Licence: None: All rights reserved

Cite this

@article{cc1eec783fdb4772b7a180a5061c18ed,

title = "Neuroblastoma arginine addiction subverts the anticancer immune response",

abstract = "High-risk neuroblastoma continues to have a poor prognosis, stimulating the ongoing development of alternative immune-therapy approaches. Despite exciting preclinical results, clinical outcomes have been less clear. Recently we identified that neuroblastoma expresses Arginase II, depleting local and systemic arginine concentrations, and suppression of autologous and engineered T cell immunity.",

author = "{De Santo}, Carmela and Francis Mussai",

year = "2016",

month = feb,

doi = "10.1080/2162402X.2015.1078967",

language = "English",

volume = "5",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Taylor & Francis",

number = "2",

}

TY - JOUR

T1 - Neuroblastoma arginine addiction subverts the anticancer immune response

AU - De Santo, Carmela

AU - Mussai, Francis

PY - 2016/2

Y1 - 2016/2

N2 - High-risk neuroblastoma continues to have a poor prognosis, stimulating the ongoing development of alternative immune-therapy approaches. Despite exciting preclinical results, clinical outcomes have been less clear. Recently we identified that neuroblastoma expresses Arginase II, depleting local and systemic arginine concentrations, and suppression of autologous and engineered T cell immunity.

AB - High-risk neuroblastoma continues to have a poor prognosis, stimulating the ongoing development of alternative immune-therapy approaches. Despite exciting preclinical results, clinical outcomes have been less clear. Recently we identified that neuroblastoma expresses Arginase II, depleting local and systemic arginine concentrations, and suppression of autologous and engineered T cell immunity.

U2 - 10.1080/2162402X.2015.1078967

DO - 10.1080/2162402X.2015.1078967

M3 - Article

C2 - 27057459

SN - 2162-4011

VL - 5

JO - OncoImmunology

JF - OncoImmunology

IS - 2

M1 - e1078967

ER -

Neuroblastoma arginine addiction subverts the anticancer immune response

Abstract

Access to Document

Fingerprint

Cite this